Alterity Therapeutics Limited American Depositary Shares (ATHE) Stock Price

ATHEStock

$4.47−21.54%52W

Market Cap$81.02M

P/E—

PEG Ratio—

Div yield—

Beta1.16

ATHE Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)16.25%

Price vs S&P 500 (4W)-3.05%

VGM Score60.89

Book Value / Share (Quarterly)$0.18

P/TBV (Annual)2.72x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)463.07%

Cash Flow / Share (Quarterly)$-0.07

Price vs S&P 500 (YTD)16.51%

Net Profit Margin (TTM)-1172.16%

EPS (TTM)$-0.06

10-Day Avg Trading Volume0.57M

EPS Excl Extra (TTM)$-0.06

Revenue Growth (5Y)91.97%

EPS (Annual)$-0.07

ROI (Annual)-36.10%

Net Profit Margin (5Y Avg)-136347.96%

Cash / Share (Quarterly)$0.16

Revenue Growth QoQ (YoY)717.39%

ROA (Last FY)-31.06%

Revenue Growth TTM (YoY)376.33%

EBITD / Share (TTM)$-0.06

ROE (5Y Avg)-80.12%

Operating Margin (TTM)-1337.31%

Cash Flow / Share (Annual)$-0.18

P/B Ratio2.15x

P/B Ratio (Quarterly)1.60x

Net Income / Employee (Annual)$-966,248

EV / Revenue (TTM)54.24x

Net Interest Coverage (TTM)-179.00x

ROA (TTM)-28.35%

EPS Incl Extra (Annual)$-0.07

Current Ratio (Annual)7.07x

Quick Ratio (Quarterly)21.98x

3-Month Avg Trading Volume0.26M

52-Week Price Return-21.54%

Revenue / Employee (TTM)$99,001

Tangible BV / Share (Quarterly)$0.11

P/S Ratio (Annual)261.30x

Asset Turnover (Annual)0.00x

52-Week High$0.56

Operating Margin (5Y Avg)-162219.75%

EPS Excl Extra (Annual)$-0.07

Tangible BV CAGR (5Y)5.72%

26-Week Price Return27.50%

Quick Ratio (Annual)6.79x

13-Week Price Return13.33%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)21.98x

Enterprise Value$48.33M

Asset Turnover (TTM)0.02x

Book Value / Share Growth (5Y)75.39%

Revenue / Employee (Annual)$35,506

Pretax Margin (Annual)-2706.71%

Cash / Share (Annual)$0.52

3-Month Return Std Dev8668.44%

Net Income / Employee (TTM)$-1,160,457

ROE (Last FY)-36.22%

Net Interest Coverage (Annual)-509.65x

EPS Basic Excl Extra (Annual)$-0.07

Receivables Turnover (TTM)26.83x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.06

Receivables Turnover (Annual)17.24x

ROI (TTM)-30.11%

P/S Ratio (TTM)93.69x

Pretax Margin (5Y Avg)-135654.32%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.05

Price vs S&P 500 (52W)-39.85%

Year-to-Date Return27.50%

5-Day Price Return0.99%

EPS Normalized (Annual)$-0.07

ROA (5Y Avg)-63.71%

Net Profit Margin (Annual)-2721.96%

Month-to-Date Return-6.42%

Cash Flow / Share (TTM)$-0.00

EBITD / Share (Annual)$-0.08

Operating Margin (Annual)-3185.21%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-79.89%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.06

P/TBV (Quarterly)1.00x

P/B Ratio (Annual)0.88x

Pretax Margin (TTM)-1161.75%

Book Value / Share (Annual)$0.53

Price vs S&P 500 (13W)10.54%

Beta1.16x

Revenue / Share (TTM)$0.00

ROE (TTM)-30.19%

52-Week Low$0.01

vGradeD

gGradeA

mGradeC

vgmGradeB

ATHE Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
ATHEAlterity Therapeutics Limited American Depositary Shares	D	A	C	$4.47
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Alterity Therapeutics Limited American Depositary Shares

Alterity Therapeutics is a clinical-stage biotechnology company developing novel treatments for Parkinson's disease and other neurodegenerative disorders. The company's proprietary pipeline targets the underlying pathology of these diseases through compounds designed to bind excess iron, reduce alpha-synuclein aggregation, and restore neuronal function. Lead programs include ATH434 and related candidates, supported by a broader drug discovery platform.